QCLS
NASDAQ · Pharmaceuticals
Q/C Technologies Inc
$3.89
+0.19 (+5.14%)
Financial Highlights (FY 2025)
Revenue
6.12M
Net Income
729.3K
Gross Margin
39.3%
Profit Margin
11.9%
Rev Growth
+22.0%
D/E Ratio
0.30
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 39.3% | 39.3% | 39.3% |
| Operating Margin | 14.3% | 14.7% | 12.9% |
| Profit Margin | 11.9% | 13.2% | 13.1% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.12M | 5.83M | 5.05M |
| Gross Profit | 2.40M | 2.29M | 1.99M |
| Operating Income | 873.8K | 856.6K | 650.3K |
| Net Income | 729.3K | 769.8K | 662.9K |
| Gross Margin | 39.3% | 39.3% | 39.3% |
| Operating Margin | 14.3% | 14.7% | 12.9% |
| Profit Margin | 11.9% | 13.2% | 13.1% |
| Rev Growth | +22.0% | +12.4% | +6.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.12M | 1.91M | 1.81M |
| Total Equity | 7.11M | 7.32M | 6.47M |
| D/E Ratio | 0.30 | 0.26 | 0.28 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.12M | 1.08M | 875.0K |
| Free Cash Flow | 457.4K | 470.8K | 287.5K |